Montreal Cognitive Assessment (MoCA): Clinical Implications in Early Alzheimer’s Disease

Dr. Ziad Nasreddine, MD FRCP(C)

Neurologist, founder of the MoCA

Carter Cassedy

Senior Client Services Associate, Author Collaboration Unit, Mapi Research Trust

A webinar presented by MoCA developer Dr. Ziad Nasreddine. Read more for webinar details and for the recording.

About the webinar

The Montreal Cognitive Assessment Test (MoCA) was created by neurologist Dr. Ziad Nasreddine in 1996, as a multi-domain cognitive screening test to help health professionals detect Mild Cognitive Impairment (MCI). In its first published validation study in 2005, while the test maintained high specificity (87%), its sensitivity to detect MCI was 90% compared to the MMSE which was 18%. The test was then validated in over 20 neurological and medical conditions, and translated into 70 languages and dialects, used in over 2,000 published studies, and was cited 13,000 times in peer reviewed journals. It is currently used in over 200 countries.

Watch this webinar, which summarises the main validation study, describes newer versions such as the electronic app, explains the importance of the training and certification program, shows clinical cases, use in clinical trials and gives a brief outline of future developments.


Dr. Ziad Nasreddine MD FRCP(C)
Neurologist and founder of the MoCA

Ziad Nasreddine graduated from Medical School and Neurology from the University of Sherbrooke. He is certified by the Medical Board of California, and by the American Board if Psychiatry and Neurology. He completed a post-doctorate fellowship in Neurobehavior at UCLA, with Dr. Jeffrey Cummings. He is the recipient of the Arista Sunlife Award of Excellence in the category of Young Quebec Professional. He is actively involved in clinical research in Alzheimer’s disease and has created and developed the Montreal Cognitive Assessment, the MoCA test, which is translated to 70 languages and dialects and now used in 200 countries around the world. The test was recently selected by the White House to assess the cognitive functions of President Donald Trump. He is affiliated with Charles LeMoyne Hospital. He is Assistant Clinical Professor in Neurology at the University of Sherbrooke, and is the founder and Director of the MoCA Clinic and Institute.

Carter Cassedy
Senior Client Services Associate, Author Collaboration Unit, Mapi Research Trust
Carter Cassedy is a Senior Client Services Associate with Mapi Research Trust’s Author Collaboration Unit. Prior to his work with the ACU he was a project manager in ICON Language Services’ Linguistic Validation team. As a member of that team he published several posters on linguistic validation methodology in outcomes-related conferences. He is a certified Localization Project Manager. He graduated from University of London, School of Oriental and African Studies with an MA in Linguistics

Who should attend?

Healthcare Professionals
Pharmaceutical Personnel
Those Interested in Cognitive Impairment, Assessment and Screening